Svelte Medical Systems Announces Treatment of First Patient in the DIRECT II Drug-Eluting Stent Study

  Svelte Medical Systems Announces Treatment of First Patient in the DIRECT II
  Drug-Eluting Stent Study

Business Wire

NEW PROVIDENCE, N.J. -- January 30, 2013

Svelte® Medical Systems today announced treatment of the first patient in the
DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable
drug Carrier Technology) study at Middelheim Hospital in Antwerp, Belgium.
DIRECT II is a prospective, randomized, multi-center clinical study comparing
the safety and efficacy of the Svelte drug-eluting coronary stent Integrated
Delivery System (IDS) to Medtronic’s Resolute Integrity™ drug-eluting stent.
The study builds on the positive 6-month results of the DIRECT I first-in-man
study which evaluated the Svelte drug-eluting coronary stent IDS in 30
patients in New Zealand. In DIRECT I, the Svelte drug-eluting coronary stent
IDS met all study endpoints and demonstrated in-stent neointimal volume
obstruction of 2.7% as assessed by intravascular ultrasound (IVUS), which is
one-third to one-half the volumetric obstruction observed in market-leading
drug-eluting stent first-in-man studies.

Providing the lowest crimped stent profile on the market, the Svelte
drug-eluting coronary stent IDS combines a thin-strut cobalt chromium stent
with a fully bioabsorbable drug carrier made of amino acids which are also
found naturally in the human body and the well-studied compound sirolimus
(rapamycin) mounted on a fixed-wire delivery system. Low profile and highly
flexible, the Svelte IDS navigates the vasculature similar to a traditional
guidewire, facilitating use of the transradial approach and general downsizing
of the access site, while allowing access to more difficult to cross and
distal lesions. The system also includes proprietary Balloon Control Band
(BCB^TM) technology providing uniform and controlled balloon growth, even at
high pressures, to safely perform direct stenting as well as high-pressure
post-dilatation, thereby minimizing procedure time and cost.

“The Svelte IDS offers a unique approach to percutaneous coronary intervention
and we look forward to evaluating the performance of the drug-eluting platform
in this highly scientific clinical study,” said Stefan Verheye, MD, PhD and
co-director of the Antwerp Cardiovascular Institute at the Middelheim Hospital
in Antwerp. “We have experience with the bare-metal version of the IDS, and
the system’s low profile and unique balloon technology have allowed us to
direct stent both simple and complex lesions.”

The DIRECT II study will enroll 159 patients at up to 20 clinical sites in
Europe and Brazil to assess the primary endpoints of Target Vessel Failure
(TVF) and in-stent Late Loss (LL). All patients are scheduled to receive
6-month clinical and angiographic follow-up, with clinical follow-up through
5-years. A subset of patients will also receive optical coherence tomography
(OCT) imaging at 6-months.

“We are excited to have the DIRECT II study underway and wish to thank our
outstanding group of investigators for their collaboration in this effort,”
said Jack Darby, President and CEO of Svelte Medical Systems. “We believe our
drug-eluting IDS, with its proprietary balloon and drug carrier technologies,
represents an easy to use, best-in-class offering which will deliver
procedural efficiencies and associated cost savings while demonstrating
long-term clinical outcomes consistent with market-leading drug-eluting
stents.”

Non-randomized data presented previously suggest the Svelte IDS significantly
reduces radiation exposure, contrast use, adjunctive interventional product
use and overall procedure time compared with conventional stent systems.
Another randomized clinical study, ACES, is currently enrolling patients to
demonstrate the positive clinical benefit and impact on resource utilization
of the bare metal Svelte IDS compared with conventional coronary stent devices
in patients with lesions eligible for direct stenting in a randomized setting.

Final 6-month data from the DIRECT I first-in-man study will be presented at
medical symposia later this year. Following CE Mark certification of the
drug-eluting IDS, the company also plans to commercialize its drug-eluting
stent on a conventional rapid-exchange delivery platform incorporating its
proprietary balloon control band and drug carrier technologies.

Headquartered in New Providence, New Jersey, Svelte Medical Systems
(www.sveltemedical.com) is a privately-held company engaged in the development
of highly deliverable balloon expandable stents. Statements made in this press
release that look forward in time or that express beliefs, expectations or
hopes regarding future occurrences or anticipated outcomes or benefits, are
forward-looking statements. A number of risks and uncertainties, such as risks
associated with product development and commercialization efforts, results of
clinical trials, ultimate clinical outcomes and benefit of the company’s
products to patients, market and physician acceptance of the products,
intellectual property protection and competitive product offerings, could
cause actual events to adversely differ from the expectations indicated in
these forward looking statements.

Contact:

Svelte Medical Systems, Inc.
Jack Darby, 908-264-2195
President and CEO
jdarby@sveltemedical.com